Strong Sales Performance
Q1 sales were stronger than February 27 guidance with 13% organic growth and 12% reported growth. Record sales were achieved in all five categories: graphs, carotid shunts, catheters, velvet homes, and patches.
International Expansion and Regulatory Success
Established new international sales offices and received MDR CE mark for autographs. European launch imminent with additional approvals expected in Australia, Canada, Singapore, and Korea by H1 2026.
Increased Sales Guidance
Raised 2025 reported sales guidance to $245 million from $239 million. Organic sales guidance increased to 13% from 10%.
Strong Financial Position
Ended Q1 with $302.5 million in cash and securities, providing strategic optionality. Cash from operations generated $9 million in the quarter.
Positive Price and Volume Dynamics
Organic sales growth driven by 9% average selling price increases and 4% unit increases. Gross margin improved by 60 basis points year over year.